S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Bear market expert makes new prediction (Ad)
UK travelers face hours-long waits for ferries to France
Credit Suisse takeover hits heart of Swiss banking, identity
Buy THIS stock before Taiwan is attacked (Ad)
Small areas reopen near Fukushima nuclear plant, few return
'War of the states': EV, chip makers lavished with subsidies
Buy THIS stock before Taiwan is attacked (Ad)
Gas prices increase in NJ, around nation amid higher demand
Lanterns and crescents: more retailers court Ramadan buyers
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Bear market expert makes new prediction (Ad)
UK travelers face hours-long waits for ferries to France
Credit Suisse takeover hits heart of Swiss banking, identity
Buy THIS stock before Taiwan is attacked (Ad)
Small areas reopen near Fukushima nuclear plant, few return
'War of the states': EV, chip makers lavished with subsidies
Buy THIS stock before Taiwan is attacked (Ad)
Gas prices increase in NJ, around nation amid higher demand
Lanterns and crescents: more retailers court Ramadan buyers
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Bear market expert makes new prediction (Ad)
UK travelers face hours-long waits for ferries to France
Credit Suisse takeover hits heart of Swiss banking, identity
Buy THIS stock before Taiwan is attacked (Ad)
Small areas reopen near Fukushima nuclear plant, few return
'War of the states': EV, chip makers lavished with subsidies
Buy THIS stock before Taiwan is attacked (Ad)
Gas prices increase in NJ, around nation amid higher demand
Lanterns and crescents: more retailers court Ramadan buyers
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Bear market expert makes new prediction (Ad)
UK travelers face hours-long waits for ferries to France
Credit Suisse takeover hits heart of Swiss banking, identity
Buy THIS stock before Taiwan is attacked (Ad)
Small areas reopen near Fukushima nuclear plant, few return
'War of the states': EV, chip makers lavished with subsidies
Buy THIS stock before Taiwan is attacked (Ad)
Gas prices increase in NJ, around nation amid higher demand
Lanterns and crescents: more retailers court Ramadan buyers
NASDAQ:TECH

Bio-Techne - TECH Stock Forecast, Price & News

$74.19
+1.76 (+2.43%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$72.84
$74.30
50-Day Range
$71.62
$82.29
52-Week Range
$68.00
$113.81
Volume
596,695 shs
Average Volume
817,941 shs
Market Capitalization
$11.67 billion
P/E Ratio
46.08
Dividend Yield
0.43%
Price Target
$104.36

Bio-Techne MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.78 Rating Score
Upside/​Downside
40.7% Upside
$104.36 Price Target
Short Interest
Healthy
1.64% of Shares Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
-1.41
Upright™ Environmental Score
News Sentiment
0.72mentions of Bio-Techne in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
21.71%
From $1.75 to $2.13 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.23 out of 5 stars

Medical Sector

15th out of 996 stocks

Biological Products, Except Diagnostic Industry

3rd out of 165 stocks


TECH stock logo

About Bio-Techne (NASDAQ:TECH) Stock

Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures purified proteins and reagent solutions most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics & Genomics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx Prostate (IntelliScore) test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use. T

Receive TECH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Techne and its competitors with MarketBeat's FREE daily newsletter.

TECH Stock News Headlines

StockNews.com Lowers Bio-Techne (NASDAQ:TECH) to Hold
"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast.
BIO-TECHNE ANNOUNCES INVESTMENT IN WILSON WOLF
ExoDx PROSTATE TEST GRANTED EXPANDED COVERAGE BY MEDICARE
Stocks are for suckers – try this instead
This has nothing to do with dividends, day trading... taking out a loan... or anything like that. What you need is about 3 seconds to execute this simple financial maneuver...
Our 7 Top Biotech Stock Picks for 2023
See More Headlines
Receive TECH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Techne and its competitors with MarketBeat's FREE daily newsletter.

TECH Company Calendar

Last Earnings
11/01/2021
Ex-Dividend for 2/27 Dividend
2/10/2023
Dividend Payable
2/27/2023
Today
4/01/2023
Next Earnings (Estimated)
5/03/2023
Fiscal Year End
6/30/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Life Sciences Tools & Services
Sector
Medical
Current Symbol
NASDAQ:TECH
CUSIP
87837710
Employees
3,000
Year Founded
1981

Price Target and Rating

Average Stock Price Forecast
$104.36
High Stock Price Forecast
$120.00
Low Stock Price Forecast
$88.00
Forecasted Upside/Downside
+40.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
9 Analysts

Profitability

Net Income
$272.05 million
Pretax Margin
28.39%

Debt

Sales & Book Value

Annual Sales
$1.11 billion
Cash Flow
$2.55 per share
Book Value
$10.84 per share

Miscellaneous

Free Float
150,276,000
Market Cap
$11.67 billion
Optionable
Optionable
Beta
1.24

Social Links


Key Executives

  • Charles R. KummethCharles R. Kummeth
    President, Chief Executive Officer & Director
  • James T. HippelJames T. Hippel
    Chief Financial Officer
  • Shane Bohnen
    Secretary , General Counsel & Senior VP
  • Brenda S. Everson
    Chief Human Resources Officer & Senior VP
  • Robert M. Gavin
    Vice President-Corporate Development













TECH Stock - Frequently Asked Questions

Should I buy or sell Bio-Techne stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bio-Techne in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TECH shares.
View TECH analyst ratings
or view top-rated stocks.

What is Bio-Techne's stock price forecast for 2023?

9 analysts have issued 1-year price objectives for Bio-Techne's shares. Their TECH share price forecasts range from $88.00 to $120.00. On average, they anticipate the company's share price to reach $104.36 in the next twelve months. This suggests a possible upside of 40.7% from the stock's current price.
View analysts price targets for TECH
or view top-rated stocks among Wall Street analysts.

How have TECH shares performed in 2023?

Bio-Techne's stock was trading at $82.88 at the start of the year. Since then, TECH shares have decreased by 10.5% and is now trading at $74.19.
View the best growth stocks for 2023 here
.

When is Bio-Techne's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our TECH earnings forecast
.

How were Bio-Techne's earnings last quarter?

Bio-Techne Co. (NASDAQ:TECH) posted its quarterly earnings results on Monday, November, 1st. The biotechnology company reported $0.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.43 by $0.03. The biotechnology company earned $257.72 million during the quarter, compared to the consensus estimate of $254.37 million. Bio-Techne had a net margin of 23.38% and a trailing twelve-month return on equity of 15.87%. During the same period in the prior year, the company posted $0.29 earnings per share.

How often does Bio-Techne pay dividends? What is the dividend yield for Bio-Techne?

Bio-Techne announced a quarterly dividend on Thursday, February 2nd. Stockholders of record on Monday, February 13th will be paid a dividend of $0.08 per share on Monday, February 27th. This represents a $0.32 dividend on an annualized basis and a dividend yield of 0.43%. The ex-dividend date is Friday, February 10th. This is an increase from the stock's previous quarterly dividend of $0.02.
Read our dividend analysis for TECH
.

Is Bio-Techne a good dividend stock?

Bio-Techne (NASDAQ:TECH) pays an annual dividend of $0.32 per share and currently has a dividend yield of 0.44%. The company does not yet have a strong track record of dividend growth. The dividend payout ratio is 19.88%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, TECH will have a dividend payout ratio of 15.02% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for TECH.

When did Bio-Techne's stock split?

Bio-Techne shares split before market open on Wednesday, November 30th 2022. The 4-1 split was announced on Tuesday, November 1st 2022. The newly minted shares were payable to shareholders after the closing bell on Tuesday, November 29th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split.

What is Charles Kummeth's approval rating as Bio-Techne's CEO?

95 employees have rated Bio-Techne Chief Executive Officer Charles Kummeth on Glassdoor.com. Charles Kummeth has an approval rating of 73% among the company's employees.

What other stocks do shareholders of Bio-Techne own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Techne investors own include Paychex (PAYX), Gilead Sciences (gild), NVIDIA (NVDA), AbbVie (ABBV), Amgen (AMGN), Abbott Laboratories (ABT), Cisco Systems (CSCO), Johnson & Johnson (JNJ), AT&T (T) and Boeing (BA).

What is Bio-Techne's stock symbol?

Bio-Techne trades on the NASDAQ under the ticker symbol "TECH."

How do I buy shares of Bio-Techne?

Shares of TECH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bio-Techne's stock price today?

One share of TECH stock can currently be purchased for approximately $74.19.

How much money does Bio-Techne make?

Bio-Techne (NASDAQ:TECH) has a market capitalization of $11.67 billion and generates $1.11 billion in revenue each year. The biotechnology company earns $272.05 million in net income (profit) each year or $1.61 on an earnings per share basis.

How many employees does Bio-Techne have?

The company employs 3,000 workers across the globe.

Does Bio-Techne have any subsidiaries?
The following companies are subsidiares of Bio-Techne: Advanced Cell Diagnostics, Advanced Cell Diagnostics Inc., B-MoGen Biotechnologies Inc., Bio-Techne China Co. Ltd, Bio-Techne Ltd., Bionostics Inc., Cliniqa, CyVek, Exosome Diagnostics, Exosome Diagnostics Inc., MoGen Biotechnologies, Novus Biologicals, Novus Biologicals LLC, ProteinSimple, ProteinSimple Ltd., QT Holdings Corporation, Quad Technologies, Research and Diagnostic Systems Inc., Shanghai PrimeGene Bio-Tech Co. Ltd., Space Import-Export Srl, Tocris Cookson Limited, and Zephyrus Biosciences.
Read More
How can I contact Bio-Techne?

Bio-Techne's mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The official website for the company is www.bio-techne.com. The biotechnology company can be reached via phone at (612) 379-8854, via email at ir@bio-techne.com, or via fax at 612-656-4400.

This page (NASDAQ:TECH) was last updated on 4/2/2023 by MarketBeat.com Staff